Editas Medicine, Inc. (EDIT) Financial Statements
Editas Medicine, Inc. (EDIT) reported trailing twelve-month revenue of $47.0M (up 20.8% year on year) and net income of -$73.9M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$120.5M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
EDITEditas Medicine, Inc.Follow EDIT — free
—
Price chart with a free account
- Market cap
- 368.6M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 9 Nov, in 16 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 31.9 | 20.5 | 90.7 | 25.5 | 19.7 | 78.1 | 32.3 | 40.5 | 47.0 | |
| Gross profit | — | — | — | — | — | — | 20.1 | — | — | |
| Research & development | 90.7 | 96.9 | 158.0 | 142.5 | 175.0 | 177.7 | 199.2 | 90.0 | 85.0 | |
| Operating income | -113.7 | -140.9 | -134.8 | -193.1 | -226.0 | -169.2 | -251.2 | -160.0 | -75.9 | |
| Pre-tax income | -110.0 | -133.7 | -116.0 | -192.5 | -220.4 | -153.2 | -237.1 | -160.1 | -73.9 | |
| Income tax | — | — | — | — | 0.0 | 0.0 | 0.0 | 0.0 | — | |
| Net income | -110.0 | -133.7 | -116.0 | -192.5 | -220.4 | -153.2 | -237.1 | -160.1 | -73.9 | |
| Diluted EPS ($) | -2.33 | -2.68 | -1.98 | -2.85 | -3.21 | -2.02 | -2.88 | -1.80 | -0.62 | |
| Diluted shares (mn) | — | — | — | 67.6 | 68.7 | 76.0 | 82.3 | 88.7 | — |
USD millions · SEC XBRL
Editas Medicine, Inc. — questions
- What is Editas Medicine, Inc.'s revenue?
- $47.0M over the twelve months to 2026-06-30, up 20.8% year on year, from its 10-Q and 10-K filings.
- What is Editas Medicine, Inc.'s net income?
- -$73.9M over the twelve months to 2026-06-30.
- What is Editas Medicine, Inc.'s free cash flow?
- -$120.5M over the twelve months to 2026-06-30.
- What are Editas Medicine, Inc.'s diluted earnings per share?
- $-0.62 over the twelve months to 2026-06-30.
Every figure on this page comes from Editas Medicine, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.